Enzyme-responsive nanomaterials for controlled drug delivery by Hu, Quanyin et al.
Enzyme-Responsive Nanomaterials for Controlled Drug Delivery
Quanyin Hua,b, Prateek S. Kattic, and Zhen Gu*,a,b
aJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and 
North Carolina State University, Raleigh, NC 27695, USA
bCenter for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, UNC 
Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 
27599, USA
cUNC MD/PhD Program, UNC School of Medicine, University of North Carolina at Chapel Hill, 
Chapel Hill, NC 27599, USA
Abstract
Enzymes underpin physiological function and exhibit dysregulation in many disease-associated 
microenvironments and aberrant cell processes. Exploiting altered enzyme activity and expression 
for diagnostics, drug targeting, and drug release is tremendously promising. When combined with 
booming research in nanobiotechnology, enzyme-responsive nanomaterials for controlled drug 
release have achieved significant development and been studied as an important class of drug 
delivery devices in nanomedicine. In this review, we describe enzymes such as proteases, 
phospholipase and oxidoreductases that serve as delivery triggers. Subsequently, we explore 
recently developed enzyme-responsive nanomaterials with versatile applications for extracellular 
and intracellular drug delivery. We conclude by discussing future opportunities and challenges in 
this area.
1. Introduction
The advent of nanomaterials-based drug delivery systems has made a seminal impact to the 
field of drug delivery.1, 2 Therapeutics and diagnostic agents incorporated in versatile 
nanoscale particles composed of dynamic nanomaterials have been developed for the 
diagnosis and treatment of cancer,3 diabetes,4, 5 bacterial infections,6 etc. Well recognized 
advantages of nanoscale particles include sustained drug delivery,7 hydrophilic and 
hydrophobic multi-drug co-incorporation and programmed-delivery,8, 9 prolonged 
circulation time in vivo, the ability to be engineered with functionalized ligands10, 11 and 
stimuli-responsive controlled drug release.12, 13 Among myriads of successful applications, 
stimuli-responsive “smart” nanomaterials have emerged as especially promising materials in 
comparison to conventional nanoscale materials due to their bio-responsive physicochemical 
nature. For example, pH-responsive nanomaterials have been used to design sensitive nano-
systems for drug delivery in cancer therapy as they can stabilize the drug at physiological 
pH and release the drug when the pH trigger point is reached.14 Due to the lower pH values 
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in the tumor microenviroment compared to normal tissue, pH-responsive nanomaterials are 
triggered and release their cargoes (e.g. drugs and diagnostic agents) specifically at the 
tumor site, therefore reducing the unwanted side effects.15, 16 Other stimuli-triggered drug 
delivery systems have been exploited extensively in biomedical research which exhibit 
reversible or irreversible changes in chemical structures and/or physical properties in 
response to a specific stimulus such as temperature,17 redox,18 ionic strength,19 electric,20 
magnetic fields21 and enzyme activity22.
A developing arena in stimuli-responsive “smart” nanomaterials is the design of 
nanomaterials whose chemical structures and/or physical properties are responsive to the 
biocatalytic action of an enzyme.23 Enzymes play critical roles in all biological and 
metabolic processes and dysregulation of enzyme expression and activity underpins the 
pathology of many diseases. Dysregulated enzymes are promising biological triggers in 
therapeutics.24 Exploiting enzymes as a trigger has a number of advantages because most 
enzymes catalyze chemical reactions under mild conditions (low temperature, neutral pH, 
and buffered aqueous solutions), where many conventional chemical reactions fail.25, 26 
Furthermore, enzymes can also exhibit exceptional selectivity for their substrates, allowing 
for specific, sophisticated, biologically inspired chemical reactions.27
In the past years, a number of nanoscale materials have been employed for the design of 
enzyme-responsive drug delivery systems including polymer materials,28–30 
phospholipids31, 32 and inorganic materials.33 The integration of nanomaterials with 
enzymatic responses can endow the formulations with bio-specificity and selectivity, 
allowing for the promising applications in diverse fields. For example, active tumor-
targeting nanoparticles integrated with site-specific enzyme-triggered moieties can 
significantly achieve enhanced accumulation at the tumor site, reduced uptake by non-
targeted tissue, as well as site-specific controlled drug release without a compromise in 
targeting efficiency and specificity.34 The nanomaterials can be rendered enzyme-responsive 
by containing moieties in their main chain or side groups which can be cleaved by enzyme. 
For instance, self-assembled nanoparticles are often incorporated with enzyme-responsive 
linkers which can be recognized by the biocatalyst or transformed by the product of the 
enzymatic reaction, in order to program the nanomaterials to release their cargo with spatial 
and temporal control.35 In other cases, especially for inorganic nanosystems, particles can be 
modified with active-targeting ligands that are sensitive to a certain enzyme.36, 37 This 
approach can further broaden the design flexibility and scope of applications by endowing 
the nanoparticle with enzyme responsive properties when the nanomaterial itself is not 
responsive to enzyme.
In this review, the most recent advances in the use of enzyme-responsive nanomaterials for a 
board range of controlled drug delivery applications are presented. First, the typical enzymes 
that can modulate drug delivery or offer a target for triggering drug release are summarized. 
Next, various nanomaterials, including polymers, lipid and inorganic materials that act as 
carriers or matrices for enzymatic-response drug delivery are surveyed. The opportunities 
and challenges of clinical applications are also discussed.
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2. Typical enzymes for controlled drug delivery
In this section, several typical classes of enzymes that serve as the triggers in enzyme-
responsive controlled drug delivery are discussed. As summarized in Fig. 1, drugs can be 
triggered to release through a variety of enzymatic implementations. Drugs can be directly 
released from different nanocarriers via site-specific enzymatic cleavage. Loading of drugs 
into nanomaterials can be achieved through covalent attachment or physical encapsulation, 
involving cross-linked matrix, self-assembled system or caged porous structure. Drug 
carriers can also be activated by enzymes to expose the targeting ligand for the subsequent 
internalization into specific cells. Additionally, enzymes can facilitate the generation of 
specific products, such as acidic environment, promoting drug release from carriers.
2.1 Proteases
Proteases are known to be involved in many physiological processes such as tissue 
remodeling, wound healing and tumor invasion.38, 39 As many diseases are characterized by 
imbalances in the expression and activity of specific protease in the diseased tissue, protease 
overexpression could potentially be exploited to allow for selective activation of advanced 
drug delivery platforms. For example, Kang et al. synthesized peptide-grafted polymers 
(conjugates) that could activate gene expression in response to protein kinase or protease 
activity. Conjugates were able to preform cellular transfection in cultivated cells and also in 
an in vivo system.40 In the protease-responsive system, the peptide side chains were 
designed as a specific substrate of a target protease and could be phosphorylated with 
hyperactivated protease upon polyplex uptake by the target cancer cell (Fig. 2A). Results 
showed that mice (6/9) bearing xenograft tumors treated with peptide-grafted polymers 
exhibited luciferase expression while none of the six mice examined showed luciferase 
activity in normal subcutaneous tissue (Fig. 2B). Protein kinase Cα, including Caspase-3 
protease, cleaved a specific sequence allowing the cationic portion of the polyplex to release 
and allowed for the activation of transgene transcription. In another case, Law et al. 
developed self-assembled peptide sequences which could release therapeutic payloads upon 
specific interaction with disease-associated proteases.41 The biologically inspired peptide 
sequence is composed of a protease cleavable region which self-assembled into a gel matrix 
in aqueous solutions. Upon addition of the targeted protease (uPA), the gel matrix could be 
digested at the substrate cleavage site, resulting in release of drugs and matrix fragments. 
Their results showed that the release of therapeutic peptide (B-r7-kla) fragment from the 
matrix was a result of the addition of enzyme and only can be observed in the presence of 
the enzyme. Furthermore, in HT-1080 cell lines, the encapsulated B-r7-kla was released 
slowly with no cytotoxic effects on cells lacking enzyme. However, enhanced drug release 
and increased cytotoxicity were observed under high uPA concentrations (500 nM) after 24 
hours.
Another class of proteases which are often employed to serve as triggers of controlled drug 
delivery include matrix metalloproteinases (MMPs). MMPs have long been associated with 
cancer-cell invasion and metastasis.42, 43 MMPs are over expressed in tumor 
microenvironments in comparison to normal tissue in most cancers.44 MMPs are proteolytic 
enzymes and their basic mechanism of action — degradation of proteins — regulates 
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various cell behaviors with relevance for cancer biology. Thus, MMPs have been widely 
employed to achieve enzyme-triggered site-specific drug release. Of note, Jiang et al. 
developed a proteolytically-activated cell-penetrating peptide-modified nanoparticle drug 
delivery system triggered by MMP-2 and MMP-9, labeled with Cy5, gadolinium, or 
both.45, 46 The reported ACPP was composed of a polycationic CPP sequence, a MMP-
sensitive peptide linker (XPLGLAG) and a polyanionic inhibitory domain (poly Glu, E9), 
forming a hairpin structure (Fig. 3). ACPP surface decorated nanoparticles had increased 
tumor specificity. Upon addition of MMP, the inhibitory domain could be dissociated at 
cleavable site, resulting in releasing the polycationic peptides and their cargo to enter the 
cells. Residual tumor and metastases as small as 200 μm could be detected by fluorescence 
imaging. The as-prepared ACPP decorated nanoparticles exhibited more than 10-fold 
cellular association and showed high in vivo contrast ratio of images corresponding well to 
the MMP distribution.
In addition to molecular imaging, the up-regulated expression of disease-associated MMP-2 
in diseased tissues and the catalytic characteristic of proteolysis have made protease-
activated drug delivery an attractive approach for tumor treatment. Recently, Gu et al. 
constructed an activatable LMWP (ALMWP, E10-PLGLAG-VSRRRRRRGGRRRR) 
modified PEG-PCL nanoparticulate drug delivery system which provided a new strategy for 
glioma treatment.47 A notable advantage of this approach is that the transport abillity of 
LMWP can be activated only in the presence of MMP-2 protease.
2.2 Phospholipases
In principle, phospholipase up-regulation has been a pathological indicator for multiple 
kinds of cancers and many other disease processes, including thrombosis, congestive heart 
failure, inflammation, neurodegeneration, and infectious pathogens.48–51 Phospholipase A2 
(PLA2) is gaining much interest as therapeutic targets as they are known to be up-regulated 
in tumors. For example, in prostate cancers, Group IIa sPLA2 is reported to be expressed at 
levels 22-fold greater than disease-free paired controls.52 The upregulation of secreted 
phospholipase A2 in tumor microenvironment mediates carcinogenesis by two pathways: 
release of arachidonic acid, which produces carcinogenic metabolites; and release of 
lysophospholipids, including lysophosphatidic acids (LPA) that induce cell growth.53, 54 
Microenvironment-upregulated PLA2s are being actively explored for the ability to produce 
environmentally responsive drug release in the tumor. Andresen et al. constructed an 
enzymatically activated liposome drug delivery system involving masked antitumor ether 
lipids (AELs) as prodrugs. AELs are activated by secretory phospholipase A2.55 AEL-
forming liposomes offered the advantages of increased cytotoxity by utilizing the membrane 
permeability of AEL drugs. They synthesized (R)-1-O-hexadecyl-2-palmitoyl-sn-glycero-3-
phosphocholine (1-O-DPPC) which was not only capable of forming liposomes but aslo 
carrying water-soluble prodrugs which could be activated by using PLA2 (proAELs) as the 
activating enzyme. Results showed that proAELs were successfully activated by PLA2 
enzymes and converted to chemotherapeutic agents. The generated AELs and fatty acid 
hydrolysis products could perturb membranes and enhance the cellular uptake of drugs 
encapsulated in the liposomes. Additionally, severe side effects (hemolysis) were limited 
because PLA2 expression specifically in tumor tissue localized activation of proAELs.
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Linderoth et al. employed the overexpressed secretory phospholipase A2 as a trigger for 
activating liposomal drug-delivery systems (Fig. 4).56 PLA2 hydrolyzed the ester group in 
the sn-2 position of glycerophospholipids and facilitated the release the drugs at specific 
tumor sites. They used a capsaicin prodrug 8 as a model drug which could aggregate into 
small unilamellar vesicles (SUVs). Their results showed that capsaicin was released from 
the phospholipids after hydrolysis with amount was found to be (90 ± 11) % (n=3) after 24 h 
when the SUVs are exposed to human sPLA2-IIA, which indicated the prodrugs are good 
substrates for sPLA2. Additonally, the prodrug could stay in the buffer solution up to two 
weeks before the addition of snake-venom sPLA2. Attributed to the covalent attachment 
between the drug and glycerophospholipid derivative, lipid prodrug could react with an ester 
group at the sn-1 position, resulting in forming a five-membered lactone and releasing the 
carried drug.
2.3 Oxidoreductase
Oxidoreductases have been widely exploited to serve as a promising target for drug delivery 
systems or biosensing due to their fundamental role in oxidative environments which are 
generated by many diseases including diabetes and cancer.57, 58 For example, glucose 
oxidase (GOx) is extensively utilized as a gate in responsive, controlled release systems or a 
diagnostic tool in the detection of glucose values.4 For example, Gu et al. applied GOx as 
the trigger to develop a nano-network which can be responsive to blood-sugar levels for 
closed-loop insulin delivery (Fig. 5).5 In that case, the injectable nano-network, prepared via 
electrostatic interaction between positively charged nanoparticle (chitosan) and negatively 
charged nanoparticle (alginate), was composed of a mixture containing nanoparticles with a 
solid core of insulin, ketal modified dextran and enzymes (GOx and Catalase). Upon 
addition of hyperglycemic state, GOx encapsulated in nanoparticles began converting 
glucose into gluconic acid, resulting in dissociation of porous nano-network and 
subsequently release of insulin. A pulsatile release profile of insulin can be achieved in 
response to gluconse concentrations in vitro. To further examine the efficacy of the insulin-
loaded nanonetwork for diabetes treatment, they utilized streptozotocin (STZ)-induced 
diabetic mice as the model to test the release of insulin in a glucose-responsive manner. In 
vivo results showed that the injectable nano-network was capable of stablizing blood glucose 
levels within the normoglycemic state for up to 10 days with a single injection. This 
glucose-responsive degradable nano-network allowed for self-regulated and long-term 
diabetes management. In another case, Gu et al. used glucose-responsive microgels for 
glucose-responsive release of insulin.59 One-step electrospray technology was utilized to 
encapsulate pH-responsive chitosan, enzyme nanocapsules and insulin into a monodisperse 
microgel. When exposed to a hyperglycemic condition, the microgel swelled as a result of 
the response of catalytic conversion of glucose into gluconic acid and subsequent 
protonation of the chitosan network. According to the in vivo studies, the microgel could 
reduce blood glucose levels in STZ-induced diabetic mice.
2.4 Other enzymes
As many diseases are characterized by imbalances in the expression and activity of specific 
enzymes in the diseased tissue, dysregulatated enzymes can be exploited to permit the 
selective activation of advanced drug delivery platforms. Recently, the enzyme penicilin G 
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amidase (PGA) was employed by Harnoy et al. to cleave the end groups of phenyl 
acetamide, which could disassemble the constructed micelles (Fig. 6A).60 The monomeric 
hybrid could be detected when enzymatic cleavage of the hydrophobic phenyl acetamide 
end groups happened. This result was supported by the change in the fluorescence of 
encapsulated Nile red dyes and fast disappearance of the amphiphilic hybrids in HPLC 
analysis in the presence of enzyme PGA. More interestingly, the formation of the fully 
degraded tetra-amine hybrids could not be observed at the relatively low enzyme PGA 
concentration (0.14 μM) after 24 h, while this formation was observed at the high enzyme 
PGA concentration of 1.4μM.
The azoreductase has received extensive attention in the field of the treatment of colon 
diseases due to the fact that azoreductase is produced by the microbialflora present in human 
colon. In a study by Rao et al, an azoreductase responsive assembly was prepared through 
the covalent coupling to azobenzene linkage and an amphiphilic diblock copolymer (Fig. 
6B).61 The copolymer assembled into a micellar structure in water but dissociated in the 
presence of the azoreductase and coenzyme NADPH due to the azobenzene-based 
copolymer junction. The azobenzene-linked poly(ethylene glycol)-b-poly(styrene) (PEG-
N=N-PS) amphiphilic copolymer was prepared through an ATRP-based macroinitiator 
approach. The assembled micellar disassembled into two segments (PEG segment and PS 
segment) when exposed to azoreductase. Due to the systems' azoreductase sensitivity and 
selectivity, the azoreductase responsive drug delivery system might have potential 
applicability in the treatment of colon diseases.
3. Enzyme responsive nanomaterials
In this section several nanomaterials that can be used as carriers for enzyme-responsive drug 
delivery systems are discussed. Popular strategies involve polymeric assemblies and 
liposomes that disintegrate, undergo structural reorganization, or cleavage to release 
functionalized ligands. Enzymes directly govern these changes or enzymatic products trigger 
advantageous changes in the physiochemical properties of the nanomaterial.
3.1 Polymeric nanoparticle
Nanotechnology, especially biodegradable polymeric nanoparticles, has emerged as a 
promising approach to augment delivery of chemical drugs and bioimaging agents.62, 63 
Polymeric nanoparticles have drawn increasing interest for their ability to deliver drugs 
within an optimal dosage range, often resulting in increased therapeutic efficacy of the drug, 
mitigated side effects, and improved patient compliance.64–66 Polyethylene glycol (PEG)-
surface modified nanoparticles, PEG is a relatively inert hydrophilic polymer, provide good 
steric hindrance preventing protein binding, reduce the rate of the reticuloendothelial system 
(RES) uptake, and increase circulation half-life of drugs.67, 68 Enzyme-responsive polymeric 
nanoparticles have been widely explored by taking advantage of 1) dysregulated enzymes in 
the disease tissue (e.g., overexpressed MMPs in most tumor tissue); 2) reversible or 
irreversible changes in chemical structures and/or properties of polymeric materials in 
response to specific enzymes. A lot of polymers have been synthetized to achieve enzyme-
responsive function for disease treatment such as cancer and diabetes. For example, Lee et 
al. constructed enzyme-responsive linkers by using 4-hydroxymandelic acid as the 
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framework.24 Then they attached the enzyme substrates to the 4-hydroxy group of the 
mandelate core, leading to spontaneous release of conjugated drugs when the substrate 
portion interacted with intracellular enzymes.
In another study, Wong et al. employed an enzyme trigger to shrink 100-nm nanoparticles to 
10-nm nanoparticles after they were exposed to the tumor microenvironment with 
overexpressed enzymes such as MMP-2 (Fig. 7A).69 In the context, type A gelatin 
crosslinked with glutaraldehyde was used as the framework to form enzyme-degradable 
nanoparticles (~100 nm). PEG-stabilized quantum dots (QDs, ~10 nm) were conjugated to 
the nanoparticle surface. When these engineered nanoparticles preferentially extravasated 
from the leaky regions of the tumor vasculature by the enhanced permeation and retention 
(EPR) effect and were exposed to the upregulated MMP-2 in the tumor environment, the 
nanoparticles were degraded by the MMP enzyme and released 10 nm quantum dots, 
resulting in enhancement of diffusive transport and deep penetration in tumor tissue. (Fig. 
7B). These enzyme-responsive, multistage nanoparticle systems allowed for additional 
tenability in the spatial control of drug delivery by changing in size, overcoming multiple 
physiological barriers thereby enhancing their penetration.
Besides shrinking the size of polymeric nanoparticles, enzymes can also be used as the 
trigger to cleave substrates and increase the size of nanoparticle. Chien et al. reported a 
polymer–peptide hybrid block copolymers self-assembled micellar nanoparticle which 
exhibited enzyme-responsive characteristics.70 In their work, a hydrophobic block and a 
hydrophilic peptide were integrated into copolymers to prepare the micelles. Micelles 
passively diffused into the tumors and accessed to overexpressed enzymes. There 
micrometer-scale aggregates were formed via cleavage of peptides in the shell of the 
micelles. Essentially the aggregates were kinetically trapped within the tumor (Fig. 7C). By 
taking advantage of the formation of a new assembly in response to the enzymatic cleavage 
of the substrate, the aggregates were retained at the tumor site as long as one week, while 
non-responsive nanoparticles would be degraded within two days. This novel type of 
disintegrable nanoparticle which can be activated in vivo by MMP-2 exhibits potential 
applications for the effective delivery of chemotherapeutic drugs and imaging agents.
In addition to chemotherapeutical drugs, enzyme-responsive nanoparticles have also been 
harnessed to delivery therapeutic proteins. Gu et al. constructed an enzymatically degradable 
cocoon-like polymeric nanocapsule by using one-pot procedure (Fig. 8).71 The nanocapsule 
(CP3-NC) was composed of an apotosis-inducing target protein—Caspase-3 (CP3), 
acrylamide (AAm), N-(3-aminopropyl) methacrylamide (APMAAm) and a CP3-degradable 
VDEVDTK peptide as cross-linker (CL-VDEVDTK)72, 73. Upon proteolytic cleavage of the 
cross-linker at 37°C, the polymeric shell dissociated and the encapsulated protein CP3 
released in functional form. In vitro results showed HeLa cells exhibited apoptotic hallmarks 
such as membrane blebbing and cell shrinkage when treated with 200 nM CP3-NC for 24 h, 
while cells treated with native CP3 or CP3-NCN (enzymatically nondegradable) showed no 
morphological changes. In another study, Biswas et al. exploited a protease-responsive 
nanocapsule for intracellular protein delivery.74 Nanocapsules were composed of monomers 
and an enzyme-degradable peptide cross-linker. Upon addition of furin (a ubiquitous 
intracellular protease), the peptide could be cleaved, leading to release of encapsulated 
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protein. Their furin degradable protein delivery vehicle successfully delivered both cytosolic 
and nuclear proteins in active forms to a variety of cell lines.
3.2 Liposome
Liposome development is rapidly evolving and dramatically changing the paradigms of drug 
delivery. The suitable sizes, unique chemical properties, large surface areas, structural 
diversity and multifunctionality of liposomes prove to be greatly advantageous for 
combating notoriously therapeutically evasive diseases such as cancer.75, 76 Because of their 
biocompatibility and ease of fabrication, liposomes are an excellent drug delivery platform 
and a number of smart liposomes have been designed to improve drug delivery efficiency 
and therapeutical efficacy.77 One of the emerging trends in smart liposome development is 
the integration of enzyme-responsive elements. As one of the earliest examples, Pak et al. 
demonstrated an enzymatically cleavable peptide–lipid N-Ac-AA-DOPE, resulted from 
covalent linkage of dioleoyl phosphatidylethanolamine DOPE and an elastase substrate. The 
liposome fusion could be achieved in the presence of human leukocyte elastase or proteinase 
K.78
Liposomes can target the tissue of interest either passively (e.g. EPR effort in tumor tissue) 
or actively via the modification of targeting molecules that recognize receptors on the cell 
surface.79, 80 Several groups have taken an approach that involves the decoration of 
liposomes with enzyme-responsive ligands which allow for controlled drug release. Wan et 
al. reported an enzymatically cleavable PEG-lipid material which was composed of a PEG 
chain, matrix metalloproteinase (MMP)-substrate peptide, and cholesterol (PPC) (Fig. 9).81 
As demonstrated, the linker peptide, Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln, between PEG and 
lipid was cleaved by MMPs including MMP-2, MMP-3, MMP-7 and MMP-9, resulting in 
the abandon of PEG chain and enhanced cellular uptake and transduction efficiency in a 
tumor specific manner. Their results indicated that PPC-modified enzyme-responsive 
anionic liposomal Ad vectors (PPC-AL-Ad) exhibited higher in vitro gene expression than 
non-cleavable PEG-lipid modified AL-Ad (PPC-AL-Ad). In another study, Terada et al. 
also used the PEGylated MMP-2 substrate peptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) to 
conjugate DOPE and prepared enzyme-responsive galactosylated liposome.82 Liposome 
could not enter into normal hepatocytes as a result of steric hindrance effect. Upon addition 
of upregulated MMPs, Liposome dissociated and subsequently was taken up. With this 
approach, it was possible to deliver a payload or increase the retention of liposomes within 
targeted cell populations via enzymatic catalyzed interactions.
3.3 Hybrid nanoparticle
The preparation of organic/inorganic hybrid nanoparticles composed of organic polymers 
and/or inorganic colloids has been recently pursued as a route to combine the advantageous 
properties of both classes of macromolecules into one nanoparticle.83, 84 A hybrid design 
(core and shell structure) could take advantages of both organic/inorganic materials in the 
core and shell. For example, in lipid-polymer hybrid nanoparticles, solid cores act as 
supports that provide mechanical stability, controlled morphology, biodegradability, 
increased surface area-to-volume ratio and narrow size distribution. In addition, the core of 
these particles, often composed of PLA or PLGA polymer, can facilitate drug delivery and 
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controlled drug release. At the same time, the lipid shell enveloping the core mimics 
biological membranes in interacting with the environment.85 Among the various emerging 
hybrid nanoparticles (e.g. lipid-polymer, gel-lipid, silica (SiO2)-polymer, iron oxides-
polymer hybrid nanoparticle), enzyme-responsive hybrid nanoparticle are gaining increasing 
attraction as a new platform for drug delivery because their enzymatic properties can be 
engineered according to interest. Most recently, Jiang et al. developed a new programmed 
hybrid-nanoparticle drug-delivery system that could co-deliver different anticancer 
therapeutics (Fig. 10). The core–shell-based Gel–Liposome was composed of a R8H3 
peptide decorated liposome core loaded with Dox and hyaluronic acid (HA) based shell 
encapsulated with trail.86 Besides, the crosslinked gel based outer shell degraded in 
concentrated hyaluronidase (HAase) that was overexpressed in tumor tissue. Degradation 
permitted the release of TRAIL and the exposure of targeted ligand R8H3-L. Subsequently, 
encapsulated Dox in the aqueous core of the modified liposome was taken up by tumor cells. 
In vivo biodistribution showed that the Dox amount in the tumor tissues using Gel-Liposome 
as delivery carrier was 5.72- and 2.70-fold higher than that of those delivered by the Dox 
solution and Dox-R8H3-Liposome after 48 h. The enzyme-responsive gel-liposome drug 
delivery system provided a potential delivery strategy to simultaneously deliver different 
antitumor drugs and achieve synergistic anticancer efficacy.
In another study, Bernardos et al. synthetized a hybrid silica mesoporous nanoparticle for 
on-command drug delivery.87 In the context, authors prepared the silica mesoporous 
nanoparticles by using an MCM-41 inorganic scaffold, containing mesopores (2–3 nm) to 
allow for the encapsulation of certain guests. The nanoscopic MCM-41-based nanoparticle 
were capped with different “saccharide” derivatives to form an enzyme-responsive hybrid 
silica mesoporous nanoparticle. This hybrid nanoparticle could open the gate and release 
cargoes when taken up by tumor cells and exposed to the specific enzymes (e.g. β-D-
galactosidase). Mondragn et al. extended this enzyme-responsive hybrid nanoparticle 
platform by synthetizing capped hybrid systems. They used two different anchoring 
strategies to functionalize MCM-41 nanoparticles functionalized with polymer ε-poly-L-
lysine (biodegradable by amidases).88 One anchoring strategy was the formation of a urea 
bonds via using lysine amino groups to decorate MCM41 nanoparticles with the ε-poly-L-
lysine backbone (solid Ru-rLys-S1). The other strategy was specific attachment of 
polypeptide to MCM-41 nanoparticles via the carboxyl terminus. Upon addition of 
proteases, both hybrid silica mesoporous nanoparticles exhibited remarkable payload release 
as a result of the hydrolysis of the polymer's amide bonds.
3.4 Inorganic nanoparticles
Inorganic nanoparticles, especially enzyme-responsive silica nanoparticles (Si-MPs), have 
great potential for useful applications in nanomedicine due to their unique responsiveness. In 
particular, enzyme-responsive Si-MPs equipped with gatekeepers are enormously appealing 
and are being implemented in controlled release systems. For instance, Park et al. reported 
an enzyme-responsive drug delivery system which could release cargoes in response to α-
amylase and lipase (Fig. 11).89 Their enzyme-responsive Si-MPs were composed of the 
surface cyclodextrin (CD) gatekeepers, functional stalks, and fluorescence probes within 
porous channels. In the presence of α-amylase, the CD which initially block the the porous 
Hu et al. Page 9













channel could be hydrolyzed. Subsequently stalk was degraded by lipase, resluting in release 
of crgoes.This strategy permitted the Si-MPs to exhibit enzyme-responsive characteristics.
Another enzyme-responsive inorganic nanoparticle which has drawn great attention is gold 
(Au) nanoparticle due to its unique chemical and physical properties including ease of 
synthesis, versatile functionalization through thiol linkages and optical properties derived 
from the localized surface plasmon resonance (LSPR) phenomenon.90, 91 Sun et al. 
developed a caspase sensitive Au nanoparticle for apoptosis imaging in live cells (Fig. 12).92 
Using caspase-3 degradable peptide substrate (DEVD) as a cross-linked bridge, a near-
infrared fluorescence dye was decorated on the surface of AuNP. Without the presence of 
enzyme, the fluorescence was quenched. When the functionalized AuNP was taken up by 
live cell, the peptide substrate could be cleaved by caspase-3 and the quenched fluorescence 
was recovered. This new enzyme-responsive system provided a potential application for 
detecting the apoptosis process due to the involvement of caspase-3 in cellular apoptosis. 
Xia et al. developed an enzyme-sensitive multimodal gold nanocage probe that allowed for 
tumor localization with photoacoustic imaging and evaluation of metastasis with NIR 
fluorescence.93 They modified the surface of gold nanocages with dye-labeled peptides 
cleavable by metalloproteases (MMPs). Upon cleavage of the peptide in the presence of 
MMP-2, the dye was released from the gold nanocage and fluorescence emission was 
recovered. Furthermore, enzyme-responsive gold nanoparticles could be harnessed to detect 
and evaluate enzymatic activity. Using endonucleases as the trigger, Xu et al. reported a 
DNA-AuNP platform as colorimetric indicators to evaluate enzymatic activity and to screen 
enzyme inhibitors.94 Two functionalized, complmentary 13-nm AuNPs were hybridized to 
form a cross-linked network of nanoparticles, purple in color. When these aggregates were 
exposed to endonuclease, the DNA-duplex interconnecting the AuNPs was degraded and a 
red color was generated due to the separation of AuNPs.
4. Enzyme-based dual/multiple responsive systems
Over the past few decades enzyme-responsive nanomaterials have emerged as one 
promising and viable technology platform for controlled drug delivery. They have been 
actively designed to accomplish enhanced drug release at target sites (spatial control) and/or 
at the right time (temporal control). In an effort to further improve controlled drug release 
performances, enzyme-based dual/multiple responsive drug delivery systems that respond to 
a combination of two or more signals, i.e pH/enzyme and temperature/enzyme, have 
recently been developed. For example, Dong et al. described a pH/Enzyme-responsive 
tumor-specific delivery system for doxorubicin (Fig. 13A).95 Cationic gelatin sensitive to 
gelatinase (GA) and Dnase I was employed to form compact nanoscale complexes (CPX1) 
with polyGC-DOX intercalation. A pH-responsive pegylated alginate was utilized to form 
CPX2 when combined with CPX1. In the presence of GA and Dnase, CPX2 could be 
digested and released DOX when pH < 6.9. According to in vivo studies, pH/enzyme dual 
responsive CPX2 enhanced the drug accumulation in tumor tissue, resulting in enhanced 
anti-cancer activity (more than 2 times anti-cancer efficiency of DOX delivered by CPX2 
when compared with free doxorubicin) and reduced the cardiotoxicity of the encapsulated 
DOX. In addition to pH/enzyme-responsive delivery systems, Chen et al. took another 
approach to design a temperature/enzyme-responsive polyvalent nucleic acid decorated 
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mesoporous silica nanoparticle (MSP) intracellular drug delivery platform (Fig. 13B).96 
They anchored a self-complementary duplex DNA to the channel of MSPs. This served as a 
cap which trapped the guest molecules within the MSP. The entrapped guest moleculars 
release was triggered either by thermal denaturation of the DNA duplex or by the presence 
of DNase I. Furthermore, their strategy extended the application of other functional nucleic 
acids to generate a multifunctional stimuli-responsive durg delivery system.
5. Conclusion
The past several years have witnessed a rapid progress in the development of enzyme-
responsive drug delivery system. These strategies exhibit tremendous therapeutic and 
detection potency for cancer or other diseases at both research and clinical levels. 
Nanomaterials, including polymers, lipids and inorganic materials, which are incorporated 
into an enzyme-responsive drug delivery system, hold incredible promise in overcoming the 
limitations and drawbacks of conventional drug delivery. Additionally, they offer 
unprecedented control over spatiotemporal drug release and delivery profiles leading to 
superior in vitro and/or in vivo theranostic efficiency62.
Despite emerging progress made in enzyme-responsive drug delivery research, there are still 
many challenges that need to be addressed. There is a tremendous variety of enzyme 
dysregulation activities in different diseases and even at different stages of one disease. 
Further fundamentally understanding of the spatial and temporal pattern of offers essential 
criteria for designing more effective and precise delivery vehicles. Second, there are many 
overlapping substrates between closely related enzyme families; more specific designs 
should be taken into account for enhancing delivery efficacy. Further, eventual translation of 
enzyme-responsive drug delivery requires comprehensive evaluation of biocompatibility of 
relevant formulations. Tailoring materials that present negligible cytotoxicity and systemic 
toxicity is highly desirable for clinical applications97–99.
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A schematic illustrating typical implementations of enzyme-responsive nanomaterials for 
controlled drug delivery. (A) Drugs can be directly released from a variety of carriers upon 
site-specific cleavage by enzymes. (B) Drug carriers can be activated by enzymes to expose 
targeting ligands for the subsequent cellular delivery. (C) Enzymes can facilitate the 
generation of specific products that result in drug release from carriers.
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(A) Schematic illustration of development and enzyme-responsive mechanism of peptide-
grafted polymers. (B) Luciferase activity in tumor site 24 h after intratumoral injection of 
peptide-grafted polymers 1 or 2 (C/A = 2.0). Arrows and circles indicate the site of 
xenografted-tumor tissue. Reproduced from ref. 40 with permission from American 
Chemical Society.
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Schematic illustration of activatable CPPs. The enzyme-responsive inhibitory domain can be 
dissociated at cleavable site, resulting in the internalization of nanoparticles. Reproduced 
from ref. 45 with permission from the National Academy of Sciences.
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Schematic illustration of the mechanism of prodrug based liposome which could be 
hydrolyzed by sPLA2 to release the drug after cyclization. Reproduced from ref. 56 with 
permission from WILEY.
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Injectable glucose-responsive nano-network for insulin delivery. (a) Ketal modified dextran-
based nanoparticle encapsulated with insulin, Gox and catalase. (b) Decoration of 
nanoparticles with chitosan and alginate, respectively. (c) Formation of Nano-network (NN) 
via electrostatic interaction and dissociation via the catalytic conversion of glucose into 
gluconic acid (d) Schematic of glucose-responsive insulin delivery for type 1 diabetes 
treatment using the STZ-induced diabetic mice model. Reproduced from ref. 5 with 
permission from American Chemical Society.
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(A) Schematic of preparation and enzyme-responsive mechanism of a smart micellar 
nanocarrier. Reproduced from ref. 60 with permission from American Chemical Society. (B) 
Schematic representation of the disruption of PEG-N=N-PS block copolymer based micellar 
in the presence of azoreductase. Reproduced from ref. 61 with permission from American 
Chemical Society.
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(A) Schematic illustration of size change of QDGelNPs and release of 10-nm QD NPs in the 
presence of MMP-2. (B) GFC chromatograms of QDGelNPs after incubation with MMP-2. 
Reproduced from ref. 69 with permission from the National Academy of Sciences. (C) 
Retention of enzyme-responsive nanoparticles in HT-1080 tumors after intratumoral 
injection. Reproduced from ref. 70 with permission from American Chemical Society.
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Schematic illustration of preparation and mechanism of protein nanocapsules. (A) 
Preparation of protein nanocapsules via in situ polymerization. (B) Typical monomers and 
cross-linker used in enzyme-responsive nanocapsule system. Reproduced from ref. 71 with 
permission from American Chemical Society.
Hu et al. Page 22














Scheme of of the enzyme-responsive liposome for the tumor cell-specific delivery of 
adenoviral vectors. Reproduced from ref. 81 with permission from Elsevier.
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Schematic illustration of mechanism of core–shell-based Gel–Liposome for programmed 
and site-specific drug delivery. Reproduced from ref. 86 with permission from WILEY.
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Si-MPs-based enzyme-responsive drug delivery system. (A) Schematic illustration of Si-
MP-CD. (B) FE-SEM image of Si-MP-CD. (C) Functional ligand on the surface of SiMP-
NBE-CD. (D) α-amylase and lipase triggered release of guest molecules from Si-MP-CD. 
Reproduced from ref. 89 with permission from American Chemical Society.
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Schematic illustration of enzyme-cleavable DEVD peptide-conjugated gold nanoparticles 
(DEVD-AuNPs). Reproduced from ref. 92 with permission from American Chemical 
Society.
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Enzyme-based dual responsive drug delivery system. (A) Schematic illustration of design of 
CPX1 and CPX2. Reproduced from ref. 95 with permission from Elsevier. (B) Release of 
cargoes from temperature/enzyme dual-responvie MSPs. Reproduced from ref. 96 with 
permission from WILEY.
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